1
Allogeneic γδ T Cell Therapy for Treatment of Patients With Advanced Solid Cancers
Condition(s):Advanced Solid TumourLast Updated:February 22, 2021Recruiting
19852 Clinical Trials in China, Page 1 of 1986
Hide Studies Not Open or Pending
2
Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma
Condition(s):Stage III Adult Soft Tissue SarcomaLast Updated:February 22, 2021Recruiting
3
Research on Operating Handle of Colonoscope
Condition(s):Colonic DiseaseLast Updated:February 22, 2021Enrolling by invitation
4
The Efficacy of N-acetylcysteine on Alleviating Symptom Caused by Lugol Chromoendoscopy
Condition(s):Esophageal Squamous Cell CarcinomaLast Updated:February 22, 2021Recruiting
5
Safety and Efficiency of γ9δ2 T Cell Against Post-transplant Acute Leukemia/Myelodysplastic Syndrome Relapse
Condition(s):Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic SyndromesLast Updated:February 22, 2021Recruiting
6
Guo’s Aortic Arch Reconstruction: The First in Man Study of WeFlow-Arch Modular Embedded Branch Stent Graft System
Condition(s):Aortic Arch; Aneurysm, DissectingLast Updated:February 22, 2021Recruiting
7
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
Condition(s):Esophagus Cancer; Esophageal Squamous Cell Carcinoma; Chemoradiotherapy; Radiation Therapy; PostoperativeLast Updated:February 22, 2021Recruiting
8
SBRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs
Condition(s):NSCLC Stage IV; EGFR T790MLast Updated:February 22, 2021Recruiting
9
Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal Carcinoma
Condition(s):Nasopharyngeal CarcinomaLast Updated:February 22, 2021Recruiting
10
Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
Condition(s):HER2-negative Breast Cancer; Gastric Adenocarcinoma; Cholangiocarcinoma; Pancreatic CancerLast Updated:February 22, 2021Not yet recruiting